Pharmacological treatment of cerebrovascular disorders was introduced at the beginning of the 20th Century. Since then, a multitude of studies have focused on the development of a consensus for a well defined taxonomy of these disorders and on the identification of specific patterns of cognitive deficits associated with them, but with no clear consensus. Nevertheless, citicoline has proved to be a valid treatment in patients with a cerebrovascular pathogenesis for memory disorders. A metanalysis performed on the entire database available from the clinical studies performed with this compound confirms the experimental evidence from the animal studies which have repeatedly described the multiple biological actions of citicoline in restoring both the cell lipid structures and some neurotransmitter functions.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Citicoline (Cognizin) in the treatment of cognitive impairment.|
|Data di pubblicazione:||2006|
|Citazione:||Citicoline (Cognizin) in the treatment of cognitive impairment / Fioravanti, Mario; Ann E., Buckley. - In: CLINICAL INTERVENTIONS IN AGING. - ISSN 1176-9092. - STAMPA. - 1:3(2006), pp. 247-251.|
|Appartiene alla tipologia:||01a Articolo in rivista|